Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia. [electronic resource]
Producer: 20200615Description: 1891-1896 p. digitalISSN:- 2473-9537
- Adenine -- analogs & derivatives
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- B-Lymphocytes -- drug effects
- Bridged Bicyclo Compounds, Heterocyclic -- pharmacology
- Down-Regulation -- drug effects
- Drug Synergism
- Enhancer of Zeste Homolog 2 Protein -- antagonists & inhibitors
- Enzyme Inhibitors -- pharmacology
- Histones -- drug effects
- Humans
- Indazoles -- pharmacology
- Indoles -- pharmacology
- Leukemia, Lymphocytic, Chronic, B-Cell -- blood
- Piperidines
- Purines -- pharmacology
- Pyrazoles -- pharmacology
- Pyridones -- pharmacology
- Pyrimidines -- pharmacology
- Quinazolinones -- pharmacology
- Signal Transduction -- drug effects
- Sulfonamides -- pharmacology
- Tumor Microenvironment -- drug effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.